Introducing the New AeroChamber Plus* Flow-Vu* Chamber
The new AeroChamber Plus* Flow-Vu* Chamber design was inspired by patients, with simplified instructions on the
product insert, more colorful artwork and enhanced product portability. All of the AeroChamber Plus* Flow-Vu* Chambers
are free from Bisphenol A (BPA) - a chemical that has been potentially linked to negative health effects.
Universal Dose Counter For Metered Dose Inhalers
Pulmo Scale quickly and accurately determines remaining doses in your metered dose inhaler.
The compact, portable and accurate Pulmo Scale displays remaining doses in your metered dose inhaler by weight. For more information or to order go to
mmsiestore.com
Report on Patient Access to Medications
International report shows gaps in access to medications persist despite improvements to Canadian public drug plans. The report, prepared by Wyatt Health Management and released by Rx&D on November 2, 2009, can be found on Rx&D's new website,
PatientsComeFirst.ca or PrioritePatients.ca.
Alvesco® (ciclesonide)
 Health Canada has approved Alvesco® (ciclesonide), a new generation inhaled corticosteroid (ICS) for the treatment of persistent asthma in adults. Alvesco® is indicated for the prophylactic management of asthma in patients 6 years of age and older. Alvesco® is a once-daily treatment for most patients and is unique because it activates on-site in the lungs with little activation in the mouth and throat. Patients using Alvesco® in clinical studies experienced an oral side-effect profile (oral thrush, hoarseness of voice) similar to that of placebo. In addition to Canada, Alvesco® is currently approved in 39 countries, including: the United Kingdom, Germany, Australia, Ireland, the Netherlands, Poland, Brazil, Chile, and Columbia.
Contact your Doctor, Pharmacist or Asthma Educator to find more information about Alvesco® .
Symbicort® Maintenance And Reliever Therapy (Symbicort® SMART™)
 Symbicort® Maintenance And Reliever Therapy (Symbicort® SMART™), a new smart approach for asthma treatment, has received Health Canada approval.
For the first time, Canadians with asthma will be able to carry one inhaler that provides both maintenance treatment and rapid symptom relief. “Symbicort® SMART™ is a new approach to asthma management that treats the underlying inflammation of the airways, one of the key causes of asthma, with every inhalation – even when used as a rescue medication.
Contact your Doctor, Pharmacist or Asthma Educator to find more information about Symbicort® SMART™.
|
